BioSpace News Archive

MMI ( Medical Microinstruments, Inc. ), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced that it will participate in the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California on January 9-12, 2023.

GeoVax Labs, Inc. announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023.

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023.

Aura Air, the smart air purification solutions provider, today announced the findings of an independent study confirming that the company’s smart air devices are highly effective in eliminating the airborne pathogens that contribute to Respiratory Syncytial Virus (RSV).

Nektar Therapeutics’ President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time.

DiscGenics, Inc. announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA on January 9 – 12, 2023.

Virpax® Pharmaceuticals, Inc. announced that it has engaged two leading physicians experienced in childhood epilepsy, Dr. Kenneth W. Sommerville and Dr. Lawrence Fried, to support the overall development plan for NobrXiol.

Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, announced the appointment of Julie Anne Smith as Chief Executive Officer and member of the Board of Directors.

Akari Therapeutics, Plc announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET.

Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic cell transplant (HCT) therapies, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT.